Individualized regenerative treatment plans designed to promote disc repair, slow degeneration, and reduce pain without surgery or repeated steroid injections.
Degenerative disc disease (DDD) develops when the intervertebral discs lose hydration and structural integrity over time. As the nucleus pulposus desiccates and the annular fibers weaken, the disc loses its shock-absorbing capacity. This creates abnormal load transfer to the facet joints, endplates, and surrounding ligaments, triggering pain, instability, and cascading degeneration through the spinal segment.
Conventional treatments typically manage symptoms temporarily: physical therapy, anti-inflammatory medications, and steroid injections may provide relief, but they don't address the underlying disc pathology. Surgery (fusion) eliminates pain by removing motion, but creates abnormal mechanical stress on adjacent segments, accelerating their degeneration.
Regenerative medicine approaches DDD differently. By delivering growth factors, stem cells, and biological signaling molecules directly into the damaged disc, we shift the local environment from breakdown toward active repair, reducing inflammation, promoting fibrocyte proliferation, and supporting disc rehydration and structural healing.
While strengthening and mobility work are essential components of treatment, physical therapy alone cannot repair a degenerated disc. Discs are avascular; they have no blood supply. Exercise improves muscle control and spinal stability, but cannot deliver the growth factors and biological signals needed to stimulate disc repair. Patients often experience temporary relief during therapy, only to relapse once the sessions end.
NSAIDs and other anti-inflammatory drugs reduce pain and swelling in the short term, but they also suppress the very inflammatory cascade that initiates healing. Long-term NSAID use inhibits tissue repair, masks progressive degeneration, and carries risks of GI bleeding, renal injury, and cardiovascular complications. You get temporary pain relief at the cost of continued disc breakdown.
Steroid injections into the epidural space reduce inflammation and nerve root irritation, but they work remotely: the medication bathes the nerve, not the damaged tissue. Like NSAIDs, repeated steroid exposure suppresses local immune function and healing. Most patients require repeat injections every 3-6 months, creating a cycle of temporary relief and progressive disc deterioration. There's no mechanism by which these injections repair the disc itself.
Fusion eliminates pain by removing segmental motion, but it doesn't repair the disc; it removes it. The adjacent segments, now forced to compensate for lost motion, experience accelerated loading and degeneration. Within 5-10 years, many fusion patients develop symptomatic disease at the levels above or below the fusion. Surgery can be necessary for certain conditions (instability, severe stenosis with myelopathy), but it's a structural trade-off, not a solution for DDD.
Regenerative medicine targets the root problem: the degenerated disc itself. By concentrating your body's own growth factors and stem cells and delivering them directly into the disc under image guidance, we activate biological repair at the cellular level.
Depending on your disc pathology and imaging findings, Dr. Crane may recommend PRP (platelet-rich plasma), BMAC (bone marrow-derived stem cell concentrate), or cellular therapy. Each approach concentrates naturally occurring molecules: growth factors (PDGF, VEGF, FGF), cytokines (IL-10), and mesenchymal stem cells that reduce inflammatory signaling and promote fibrocyte proliferation, collagen synthesis, and disc matrix restoration.
The treatment is delivered intradiscally (directly into the nucleus) or paravertebrally (into the annulus or surrounding structures) under fluoroscopic or ultrasound guidance to ensure precision. This isn't regional anesthesia or anti-inflammatory suppression; it's targeted biological stimulation of repair in the exact tissue causing your pain.
Over 6-12 weeks following treatment, disc biology shifts from catabolism (breakdown) to anabolism (repair). Inflammation decreases, hydration improves, and structural integrity begins to stabilize. Most patients see meaningful functional improvement by 8-12 weeks, with continued gains through 6 months.
Your first consultation with Dr. Crane includes a thorough history, physical examination, and review of your imaging (MRI, CT). He'll identify which discs are degenerated, assess the severity of disc loss and inflammation, and determine whether regenerative therapy is appropriate for your specific anatomy and condition. If you don't have recent imaging, we'll order it to guide treatment planning.
On treatment day, you'll receive mild sedation and local anesthesia. Using real-time imaging (fluoroscopy or ultrasound), Dr. Crane guides a small needle into the damaged disc. Once proper needle position is confirmed, the regenerative concentrate (PRP, BMAC, or cellular therapy) is carefully injected. The entire procedure takes 20-30 minutes. You'll rest briefly and are typically discharged the same day with post-procedure instructions.
Severely degenerated discs, those with complete loss of hydration or advanced structural collapse, cannot be fully "reversed" by regenerative medicine or any non-surgical treatment. However, many discs in early-to-moderate degeneration can stabilize, rehydrate, and regain functional integrity. The goal is to arrest disease progression, reduce inflammation, and restore biomechanical stability. This typically eliminates pain and restores function even if the disc doesn't return to a completely normal state.
Epidural steroid injections deliver anti-inflammatory medication to the nerve root, reducing irritation and pain but not addressing disc pathology. The steroid suppresses inflammation remotely and temporarily. Intradiscal PRP delivers growth factors directly into the damaged disc, activating repair at the cellular level. The mechanism is fundamentally different: steroid injections suppress symptoms; PRP stimulates tissue healing. PRP has no anti-inflammatory suppression; it works with your body's healing response, not against it.
Most insurance plans do not currently cover regenerative treatments like PRP or BMAC for disc disease, as these therapies are still considered emerging. However, we work with patients to explore all options: some plans cover specific procedures under certain conditions, and we can discuss self-pay options and financing. During your consultation, we'll review your specific plan and provide transparent cost estimates before any treatment begins.
Many patients see meaningful improvement with a single intradiscal injection. However, depending on the extent of degeneration, your response to the initial treatment, and your symptom pattern, a second treatment 4-6 weeks later may be recommended. Dr. Crane will assess your progress at 6-8 weeks post-treatment and discuss whether additional therapy is beneficial. The goal is to achieve stable, lasting improvement with the minimum number of procedures necessary.
Every patient with degenerative disc disease deserves an honest evaluation of their options, including surgery. Let's talk about whether regenerative medicine can help you.